Results of treatment of acute myeloid leukemia in central part of Iran

Ashrafi, Farzaneh; Shahnazari, Razieh; Samimi, Mojgan Alam; Mehrzad, Valliollah

doi:10.4103/2277-9175.114194

Cited by 5 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the study of Allahyari et al was performed on various subtypes of AML rather than only APL. In a study on 95 AML patients in Iran, median overall survival was reported 13 months, with one-year and two-year survival rates of 51% and 26% respectively (15). This was considerably lower than the survival observed in our study which may be due to the heterogeneity of AML subtypes in the before mentioned study.…”

Section: Discussioncontrasting

confidence: 86%

The Survival of Patients with t(15;17)(q22;q12) Positive Acute Promyelocytic Leukemia: A Study in North-East of Iran

Ayatollahi¹,

Bazi²,

Sadeghian³

et al. 2020

Iran J Pathol

View full text Add to dashboard Cite

Scan to discover online Background & Objective: Acute promyelocytic leukemia (APL) with t(15;17)(q22;q12) is a relatively common subtype of acute myeloid leukemia (AML). Here, our objective was to ascertain the survival of patients with this leukemia in northeast of Iran. Methods: Survival rates of 42 APL patients with t(15;17)(q22;q12) were assessed. Clinical information was obtained from archived medical records. Statistical analysis was performed by SPSS 18 software using log-ranked test and Kaplan Maier survival analysis. Results: Females and males comprised 49% and 51%, respectively. The mean age at diagnosis was 34.3±14.1 years old. During the study period, 17 demises occurred in males, while this number was 7 in females. The mean survival of patients (month) was 23.22±3.57 (95% CI: 16.21±30.2). The five-year survival rate obtained 30%. Regarding demographic and clinical features, the highest rates of 5-year survival were recorded in patients with 20-35 years old (47.6%), males (51%), white blood cell count <10× 10 9 /l (48%), and platelet count >140× 10 9 /l (100%). Conclusion: Younger age, lower WBC count and higher platelet count were significantly associated with longer survival in AML patients with t(15;17)(q22; q12).

show abstract

Section: Discussioncontrasting

confidence: 86%

The Survival of Patients with t(15;17)(q22;q12) Positive Acute Promyelocytic Leukemia: A Study in North-East of Iran

Ayatollahi¹,

Bazi²,

Sadeghian³

et al. 2020

Iran J Pathol

View full text Add to dashboard Cite

show abstract

“…Our study findings are similar to previously reported data. In contrast to our results, a few studies found NPM1 mutations incidence as low as 4.2%, 6% and 8% [22,23].…”

Section: Discussioncontrasting

confidence: 99%

Conventional Cytogenetic and Molecular Analysis in Acute Myeloid Leukemia (AML) and Their Association with Overall Survival

Shakeri

Javan

Ayatollahi

et al. 2021

Acta Medica Bulgarica

View full text Add to dashboard Cite

Background: Conventional cytogenetic is one of the most important diagnostic tools for predicting the overall survival of the patients. Molecular genetics in acute myeloid leukemia (AML) has provided insights into the molecular mechanism of leukemogenesis. In this study we aimed to investigate the impact of cytogenetic and molecular methods on the survival of patients with de novo established AML in order to achieve a useful marker or test in the process of predicting the disease course. Material and methods: Eighty newly diagnosed AML patients who were treatment naive entered the study. Cytogenetic and molecular studies such as, the conventional karyotyping, sequencing and reverse transcriptase real time quantitative PCR (RT-qPCR) were included. Overall survival was calculated by Kaplan-Maier technique and the data were analyzed by SPSS.V.19. Results: Among 80 patients, 36 (45%) were female and 44 (55%) were male patients. Patients’ median age was 29 years, ranging from 1 to 76 years. The mean overall survival was 19 months (95% CI: 1523 months). The 1-year AML survival rate was 61%. There were significant differences in overall survival between the NPM1-mutated groups compared to the patients without any mutations (19% versus 61%) (p < 0.032). Conclusion: This study makes a significant contribution in assessing the prognostic value of cytogenetic and molecular markers. This study showed the heterogeneity of de novo AML that involved various factors and prevalence of distinct cytogenetic subgroups. Our data in comparison with other population-based studies, confirmed a differential distribution of cytogenetic and molecular classification indicating geographic heterogeneity.

show abstract

“…In this study, t(15;17) (q22;q21) had the most frequency in AML patients (37.7%). A study reported that the 1-and 2-year survival rate for AML patients was 51% and 26%, respectively (Ashrafi et al, 2013). Two studies (Juliusson et al, 2009;Alibhai et al, 2009), reported 3-year survival rates was between 9-10% and 5-year survival was 3-8% in patients≥60 years, compared with 5-year survival rates of up to 50% for younger patients.…”

Section: Discussionmentioning

confidence: 99%

“…Patients in other research (Byrd et al, 1998), had a median age of 64 years (range, 16-79 years), 50% male. Three studies in Iran reported that: In study 1 (Ashrafi et al, 2013), patients' median age was 37 years (range, 15-68 years), 64.2% were male. In study 2 (Ayremlou et al, 2012), the mean age in AML patients was 44.7 years that 56.3% were male.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Factors and Survival in Acute Myeloid Leukemia Cases: a Report from the Northeast of Iran

Allahyari

Tajeri²,

Sadeghi³

2016

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

In all patients, 76% had fever and 50% consumed amphotericin. T(15;17)(q22;q21) had the most prevalence (37.7%) compared to other forms. Out of 92 patients, O+(30.4%) was the most common blood group and AML-M5 (28.3%) the most common subtype. There was a significant difference in survival based on WBC and consumption of amphotericin B (P<0.05). Conclusions: WBC level, fever and consumption of amphotericin B proved to be factors for survival of AML patients. The mean age for patients in Iran is lower than other areas in the World and also survival in this study was higher than in other studies.

show abstract

Results of treatment of acute myeloid leukemia in central part of Iran

Cited by 5 publications

References 13 publications

The Survival of Patients with t(15;17)(q22;q12) Positive Acute Promyelocytic Leukemia: A Study in North-East of Iran

The Survival of Patients with t(15;17)(q22;q12) Positive Acute Promyelocytic Leukemia: A Study in North-East of Iran

Conventional Cytogenetic and Molecular Analysis in Acute Myeloid Leukemia (AML) and Their Association with Overall Survival

Prognostic Factors and Survival in Acute Myeloid Leukemia Cases: a Report from the Northeast of Iran

Contact Info

Product

Resources

About